fierce biotech - Robuta Search

https://www.fiercebiotech.com/ Fierce Biotech News & Reports Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on Fierce Biotech as their must-read source for the latest news,... fierce biotech news reports https://www.fiercebiotechweek.com/event/contact/mary-jane-hinrichs Mary Jane Hinrichs | Fierce Biotech Week mary jane fierce biotech week https://www.fiercebiotechweek.com/event/contact/shannon-simpson Shannon Simpson | Fierce Biotech Week shannon simpson fierce biotech week https://www.fiercebiotechweek.com/event/contact/paula-markos Paula Markos | Fierce Biotech Week fierce biotech paula markos week https://www.fiercebiotechweek.com/event/contact/youssef-idelcaid Youssef Idelcaid | Fierce Biotech Week fierce biotech youssef week https://www.fiercebiotechweek.com/event/contact/diana-gallagher-md Diana Gallagher, MD | Fierce Biotech Week fierce biotech diana gallagher md week https://www.fiercebiotechweek.com/event/contact/liza-micioni Liza Micioni | Fierce Biotech Week fierce biotech liza week https://www.fiercebiotechweek.com/fiercebiotechweekcom/fierce-outsourcing-awards Fierce Outsourcing Awards | Fierce Biotech Week outsourcing awards fierce biotech week https://www.fiercebiotech.com/biotech/taysha-gene-therapies-hits-ground-running-30m-15-programs Taysha Gene Therapies hits the ground running with $30M, 15 programs | Fierce Biotech Apr 29, 2020 - The team that developed Zolgensma is back for round two. https://www.fiercebiotech.com/keyword/concert-pharmaceuticals Concert Pharmaceuticals | Fierce Biotech concert pharmaceuticals fierce biotech https://www.fiercebiotech.com/biotech/qlaris-armed-25m-round-pushes-new-glaucoma-drug-into-clinic Qlaris, armed with $25M round, pushes new glaucoma drug into clinic | Fierce Biotech Apr 15, 2021 - Patients with glaucoma have two main options: eye drops and surgery, both of which aim to reduce pressure in the eye that can lead to vision loss. https://www.fiercebiotech.com/keyword/esc-2022 ESC 2022 | Fierce Biotech esc fierce biotech https://www.fiercebiotech.com/keyword/fennec-pharmaceutical Fennec Pharmaceutical | Fierce Biotech fennec pharmaceutical fierce biotech https://www.fiercebiotech.com/keyword/glooko Glooko | Fierce Biotech fierce biotech https://www.fiercebiotech.com/keyword/monoclonal-antibodies monoclonal antibodies | Fierce Biotech monoclonal antibodies fierce biotech https://www.fiercebiotech.com/keyword/almac-group Almac Group | Fierce Biotech group fierce biotech https://www.fiercebiotech.com/keyword/sales-forecasting sales forecasting | Fierce Biotech sales forecasting fierce biotech https://www.fiercebiotech.com/keyword/organ-transplant-rejections organ transplant rejections | Fierce Biotech organ transplant rejections fierce biotech https://samoawellnessreport.com/article/911073837-annovis-ceo-to-present-on-multi-protein-model-of-alzheimer-s-disease-at-fierce-biotech-week-2026 Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026 |... https://www.fiercebiotech.com/keyword/nephropathy nephropathy | Fierce Biotech nephropathy fierce biotech https://www.fiercebiotech.com/medtech/mirvie-rna-analysis-tech-can-predict-preterm-birth-two-months-advance-study-finds Mirvie mRNA study predicts premature births 2 months in advance | Fierce Biotech Apr 13, 2022 - As many as 10% of births in the U.S. https://www.fiercebiotech.com/biotech/takeda-sets-aside-15b-for-u-s-buys-after-topsy-turvy-r-d-week-ft Takeda sets aside $15B for U.S. buys after topsy-turvy R&D week: FT | Fierce Biotech Sep 14, 2016 - Takeda has had something of a busy start to September after ditching an option on an early-stage drug development pact with MacroGenics. https://www.fiercebiotech.com/biotech/technology-innovation Technology Innovation | Fierce Biotech Nov 19, 2025 - SandboxAQCEO: Jack Hidary Based: Palo Alto, CAFounded: 2021SandboxAQ uses advanced technology to solve advanced problems. In life sciences, that includes... technology innovation fierce biotech https://newsramp.com/curated-news/annovis-bio-to-present-multi-protein-alzheimer-s-approach-at-fierce-biotech-week/01236e253e79d36cf6f8c8a0f270cf74 Annovis Bio to Present Multi-Protein Alzheimer's Approach at Fierce Biotech Week | Newsramp.com Annovis Bio (NYSE: ANVS) CEO to present at Fierce Biotech Week about buntanetap, a multi-protein inhibitor for Alzheimer's and Parkinson's. Learn about the... https://www.fiercebiotech.com/keyword/vedanta-biosciences Vedanta Biosciences | Fierce Biotech vedanta biosciences fierce biotech https://www.fiercebiotech.com/keyword/owlet-baby-care Owlet Baby Care | Fierce Biotech baby care owlet fierce biotech https://www.fiercebiotech.com/biotech/boehringer-ingelheim-and-epizyme-launch-300m-precision-oncology-program Boehringer Ingelheim and Epizyme launch $300M precision oncology program | Fierce Biotech Nov 15, 2018 - In a worldwide collaboration worth up to $300 million or more, Boehringer Ingelheim is expanding its precision oncology programs by tapping Epizyme for... precision oncology program boehringer ingelheim launch https://www.fiercebiotech.com/keyword/nuvation-bio Nuvation Bio | Fierce Biotech bio fierce https://www.fiercebiotech.com/keyword/short-bowel-syndrome short bowel syndrome | Fierce Biotech short bowel syndrome fierce biotech https://www.fiercebiotech.com/biotech/sanofi-kicks-off-new-immunology-drug-discovery-journey-stanford-pact Sanofi kicks off new immunology research journey with Stanford pact | Fierce Biotech May 6, 2021 - Drugs often take more than a decade to move through the pipeline, and Sanofi is kicking off the process anew in immunology through a scientific exchange... immunology research https://www.fiercebiotech.com/biotech/grifols-ponies-up-80m-for-polyclonal-antibody-biotech-gigagen-0 Grifols ponies up $80M for polyclonal antibody biotech GigaGen | Fierce Biotech Mar 10, 2021 - Grifols picked up a 44% stake in GigaGen in 2017 when the duo teamed up to develop polyclonal antibodies under a $50 million pact. polyclonal antibody grifols ponies biotech fierce https://www.fiercebiotech.com/partnering/boehringer-bets-262m-on-arena-s-cns-discovery-platform Boehringer bets $262M on Arena's CNS discovery platform | Fierce Biotech Jan 13, 2016 - German pharma giant Boehringer Ingelheim is wagering up to $262 million on a discovery-stage project with the struggling Arena Pharmaceuticals, hoping to... discovery platform boehringer bets arena https://www.fiercebiotech.com/keyword/dengue-fever Dengue fever | Fierce Biotech dengue fever fierce biotech https://www.fiercebiotech.com/research/regimmune-finds-12m-alternative-research-money REGiMMUNE finds $12M in 'alternative' research money | Fierce Biotech Dec 9, 2008 - Tough financial times in the research field demand some outside-the-box thinking. For REGiMMUNE, it also helped to have some outside-the-U.S. connections. The... finds alternative research money fierce https://www.fiercebiotech.com/keyword/newlink-genetics NewLink Genetics | Fierce Biotech genetics fierce biotech https://www.fiercebiotech.com/medtech/boston-scientific-snaps-up-nvision-medical-deal-worth-275m Boston Scientific snaps up nVision Medical in deal worth $275M | Fierce Biotech Apr 16, 2018 - Boston Scientific is shelling out up to $275 million to acquire nVision Medical, the developer of the first and only FDA-approved device to collect cells from... boston scientific https://www.fiercebiotech.com/research/new-antibody-cuts-mother-to-fetus-zika-transmission-mice New antibody cuts mother-to-fetus Zika transmission in mice | Fierce Biotech Nov 8, 2016 - An NIAID-funded team has discovered a Zika antibody that reduces mother-to-fetus transmission of the virus in pregnant mice. https://www.fiercebiotech.com/keyword/destiny-pharma Destiny Pharma | Fierce Biotech destiny pharma fierce biotech https://www.fiercebiotech.com/medtech/overjet-nets-fda-clearance-for-gum-disease-spotting-deep-learning-software Overjet nets FDA clearance for gum-disease-spotting deep learning software | Fierce Biotech May 21, 2021 - Say cheese: The FDA has authorized one of the first artificial-intelligence-based technologies for use in dentistry, a software platform from dental developer... https://www.fiercebiotech.com/biotech/urovant-seeks-150m-ipo-just-a-year-after-launch Urovant seeks $150M IPO just a year after launch | Fierce Biotech Jul 15, 2018 - Urovant Sciences came to life in June last year with a focus on urologic disorders and a phase 3 overactive bladder med licensed from Merck. urovant seeks ipo https://www.fiercebiotech.com/biotech/kkr-viking-global-lead-299m-round-for-bridgebio KKR, Viking Global lead $299M round for BridgeBio | Fierce Biotech Jan 23, 2019 - BridgeBio Pharma has bagged a whopping $299.2 million kkr viking global lead round https://www.fiercebiotech.com/biotech/zs-pharma-raises-46-million-series-c-financing ZS Pharma raises $46 million in Series C Financing | Fierce Biotech Oct 24, 2012 - ZS Pharma raises $46 million in Series C Financing Capital to fund Phase III Clinical Trial targeting kidney and liver disease (FORT WORTH, Texas) October 23,... in series zs pharma raises million https://www.fiercebiotech.com/medical-devices/ge-backs-depression-neurostim-startup-neuronetics-34m-series-f-round GE backs depression neurostim startup Neuronetics in $34M Series F round | Fierce Biotech Apr 27, 2015 - Neuronetics has closed a $34.3 million Series F round to further commercialize its NeuroStar transcranial magnetic stimulation therapy system to treat... https://www.fiercebiotech.com/keyword/nivalis-therapeutics Nivalis Therapeutics | Fierce Biotech nivalis therapeutics fierce biotech https://www.fiercebiotech.com/biotech/solid-bio-safely-doses-dmd-gene-therapy-after-exiting-fda-hold Solid Bio safely doses DMD gene therapy after exiting FDA hold | Fierce Biotech Mar 16, 2021 - Solid Biosciences has given its Duchenne muscular dystroph https://www.fiercebiotechweek.com/event/fierce-biotech-week-2026/session/partner-presentation-1 From Protocol to Execution: Navigating Clinical Complexity with End-to-End AI | Fierce Biotech Week https://www.fiercebiotech.com/keyword/kura-oncology Kura Oncology | Fierce Biotech kura oncology fierce biotech https://www.fiercebiotech.com/medtech/zimmer-biomet-steps-surgical-tech-first-ai-powered-software-tool Zimmer Biomet rolls out first AI tool to predict post-op outcomes | Fierce Biotech Mar 10, 2022 - After cleaving off its spinal and dental businesses into the newly independent company ZimVie, Zimmer Biomet is now going all-in on its remaining orthopedic... https://www.fiercebiotech.com/keyword/liquid-biopsy liquid biopsy | Fierce Biotech liquid biopsy fierce biotech https://www.fiercebiotech.com/medtech/medtronic-gets-fda-green-light-for-ipad-based-pacemaker-programmer Medtronic gets FDA green light for iPad-based pacemaker programmer | Fierce Biotech May 6, 2019 - The FDA has cleared a new device manager platform from Medtronic that allows physicians to program and download data from compatible cardiac implants using an... green light for ipad https://www.fiercebiotech.com/keyword/probiodrug Probiodrug | Fierce Biotech fierce biotech https://www.fiercebiotech.com/keyword/braf-inhibitor BRAF inhibitor | Fierce Biotech braf inhibitor fierce biotech https://www.fiercebiotech.com/research/regeneron-scientists-pinpoint-genes-related-to-covid-19-susceptibility-and-severity Regeneron scientists pinpoint genes related to COVID-19 susceptibility and severity | Fierce Biotech Oct 28, 2020 - Why do some people get SARS-CoV-2 infection, but others can fight it off? https://www.fiercebiotech.com/keyword/igm-biosciences IGM Biosciences | Fierce Biotech igm biosciences fierce biotech https://www.fiercebiotech.com/keyword/neurological-disorders neurological disorders | Fierce Biotech neurological disorders fierce biotech https://www.fiercebiotech.com/keyword/quanta-dialysis-technologies Quanta Dialysis Technologies | Fierce Biotech quanta dialysis technologies fierce biotech https://www.fiercebiotech.com/keyword/phase-3 phase 3 | Fierce Biotech phase fierce biotech https://www.fiercebiotech.com/keyword/empress-therapeutics Empress Therapeutics | Fierce Biotech empress therapeutics fierce biotech https://www.fiercebiotech.com/keyword/anticoagulant anticoagulant | Fierce Biotech anticoagulant fierce biotech https://www.fiercebiotech.com/medical-devices/st-jude-touts-favorable-outcomes-study-cardiomems-heart-failure-monitor St. Jude touts favorable outcomes study of CardioMEMS heart failure monitor | Fierce Biotech Apr 4, 2016 - St. Jude Medical touted an independent study from a New York healthcare system during the annual meeting of the American College of Cardiology, which showed... https://www.fiercebiotech.com/special-report/top-10-biotech-ipos-2019 Top 10 biotech IPOs in 2019 | Fierce Biotech Feb 24, 2020 - The big question at the start of 2019 was whether the IPO window would stay open for biotech companies, particularly those seeking to pull off ever-larger IPOs... top biotech ipos fierce https://www.fiercebiotech.com/keyword/cambridge-biomedical Cambridge Biomedical | Fierce Biotech cambridge biomedical fierce biotech https://www.fiercebiotech.com/biotech/ovid-seeks-metamorphosis-into-public-company-86m-ipo Ovid seeks metamorphosis into public company with $86M IPO | Fierce Biotech Apr 12, 2017 - Ovid Therapeutics, which already has deals and backing from Takeda and Lundbeck, as well as a pharma vet CEO in the form of former Teva chief Jeremy Levin, is... public company ovid seeks metamorphosis https://www.fiercebiotech.com/biotech/orchard-therapeutics-launches-raises-33m-will-face-off-gsk Orchard Therapeutics launches, raises $33M, will face off with GSK | Fierce Biotech May 3, 2016 - Orchard Therapeutics burst into life today with a little seed money and backing from several major hospitals and universities as it looks to take on the... https://www.fiercebiotech.com/biotech/novartis-pays-150m-to-license-akcea-ionis-cardiac-disease-drug Novartis pays $150M to license Akcea-Ionis cardiac disease drug | Fierce Biotech Feb 25, 2019 - Novartis has taken up its option to license antisense oligonucleotide TQJ230, triggering a $150 million payout that Akcea Therapeutics will share with Ionis... https://www.fiercebiotech.com/keyword/chief-operating-officer chief operating officer | Fierce Biotech chief operating officer fierce biotech https://www.fiercebiotech.com/keyword/obseva ObsEva | Fierce Biotech fierce biotech https://www.fiercebiotech.com/r-d/global-fear-of-ebola-outbreak-stokes-a-frenzy-of-new-r-d-production-plans Global fear of Ebola outbreak stokes a frenzy of new R&D, production plans | Fierce Biotech Aug 21, 2014 - With media organizations broadcasting lurid images of the Liberian military's violent effort to enforce a quarantine in an effort to corral Ebola in the slums... https://www.fiercebiotech.com/data-management/iphone-based-parkinson-s-study-shares-6-months-of-data-on-9-500-participants IPhone-based Parkinson's study shares 6 months of data on 9,500 participants | Fierce Biotech Mar 4, 2016 - Sage Bionetworks has released the first tranche of data from its iPhone-based study of Parkinson's disease. With 9,520 participants consenting to share their... https://www.fiercebiotech.com/biotech/alta-raises-130m-for-its-new-biotech-vc-fund-missing-its-200m-goal Alta raises $130M for its new biotech VC fund, missing its $200M goal | Fierce Biotech Jun 13, 2018 - Healthcare venture capital firm Alta Partners has launched a new fund focused on companies developing new therapeutics and health technology services. https://www.fiercebiotech.com/biotech/end-line-looms-for-aradigm-as-it-files-for-bankruptcy End of the line looms for Aradigm as it files for bankruptcy | Fierce Biotech Feb 19, 2019 - A year after a major knockback from the FDA for its lead inhaled antibiotic product and protracted efforts to try to resurrect the program, Aradigm has filed... end of the line https://www.fiercebiotech.com/keyword/nabriva-therapeutics Nabriva Therapeutics | Fierce Biotech therapeutics fierce biotech https://www.fiercebiotech.com/keyword/kadcyla Kadcyla | Fierce Biotech fierce biotech https://www.fiercebiotech.com/biotech/oncoresponse-raises-40m-for-cancer-patient-sourced-antibodies OncoResponse raises $40M for cancer patient-sourced antibodies | Fierce Biotech Sep 11, 2018 - Texas biotech OncoResponse has raised $40 million in second-round financing to develop drugs based on antibodies taken from canc for cancer raises patient sourced antibodies https://www.fiercebiotech.com/keyword/cagrisema CagriSema | Fierce Biotech fierce biotech https://www.fiercebiotech.com/keyword/biopsy biopsy | Fierce Biotech biopsy fierce biotech https://www.fiercebiotech.com/biotech/novavax-craters-after-phase-iii-rsv-f-vaccine-failure-seeks-path-forward Novavax craters after Phase III RSV F vaccine failure; seeks path forward | Fierce Biotech Sep 16, 2016 - Novavax ($NVAX) saw its shares plummet afterhours yesterday when it announced a late-stage test of its infectious respiratory disease vaccine missed all of its... https://www.fiercebiotech.com/keyword/nih NIH | Fierce Biotech nih fierce biotech https://www.fiercebiotech.com/research/treating-melanoma-by-turning-off-nras-activator Treating melanoma by turning off a common mutation | Fierce Biotech Jan 31, 2019 - Mutations in the NRAS gene account for about 25% of melanoma cases. But so far, drugs designed to rein in the rogue NRAS protein have yielded little success. treating melanoma turning common mutation